Neumora Therapeutics, Inc. (NMRA)
0.5033
+0.02
(+3.35%)
USD |
NASDAQ |
Nov 06, 16:00
0.4955
-0.01
(-1.55%)
After-Hours: 20:00
Neumora Therapeutics Cash from Operations (Quarterly) : -39.97M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -39.97M |
| March 31, 2026 | -46.40M |
| December 31, 2025 | -47.96M |
| September 30, 2025 | -46.63M |
| June 30, 2025 | -52.40M |
| March 31, 2025 | -59.45M |
| December 31, 2024 | -50.34M |
| September 30, 2024 | -33.48M |
| June 30, 2024 | -56.16M |
| March 31, 2024 | -42.96M |
| December 31, 2023 | -51.44M |
| Date | Value |
|---|---|
| September 30, 2023 | -47.77M |
| June 30, 2023 | -31.02M |
| March 31, 2023 | -33.04M |
| December 31, 2022 | -30.37M |
| September 30, 2022 | -25.76M |
| June 30, 2022 | -26.58M |
| March 31, 2022 | -32.19M |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | -15.24M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| EyePoint, Inc. | -62.35M |
| Context Therapeutics, Inc. | -7.020M |
| LENZ Therapeutics, Inc. | -22.31M |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 142.89M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 9.735M |
| Free Cash Flow | -180.96M |
| Free Cash Flow Per Share (Quarterly) | -0.2159 |
| Free Cash Flow to Equity (Quarterly) | -39.85M |
| Free Cash Flow to Firm (Quarterly) | -38.15M |
| Free Cash Flow Yield | -206.8% |